The common sense model applied to hepatitis C: a qualitative analysis of the impact of disease comparison and witnessed death on hepatitis C illness perception

Harm Reduction Journal

Alain H. Litwin²  Deena Peyser¹  Abigail Batchelder³  Stella A. Safo² 

[1] Rutgers University, Newark, NJ, USA;Department of General Internal Medicine, Albert Einstein College of Medicine, 111 East 210 St., Bronx 10467, NY, USA;University of California, San Francisco, CA, USA

关键词: Substance use;    People who inject drugs (PWID);    Treatment barriers;    Illness perception;    HIV/AIDS;    Hepatitis C (HCV);   

Others  :  1221142
DOI  :  10.1186/s12954-015-0054-1

 received in 2014-12-23, accepted in 2015-06-14,  发布年份 2015

【 摘 要 】

Background

Hepatitis C virus (HCV) accounts for 15,000 deaths in the United States yearly because people living with HCV are not identified in time to seek treatment, are ineligible for or refuse treatment, or face structural impediments to obtaining treatment such as lack of access to health care or lack of insurance. People who inject drugs (PWID) comprise a large proportion—estimates of up to 60–70 %—of current and new HCV infected individuals and face many barriers to completing HCV treatment.

Methods

We conducted 30 qualitative semi-structured interviews of current and former PWID seeking HCV treatment at an opioid-agonist treatment facility in New York City. We used thematic analysis, informed by grounded theory, to examine perceptions of HCV and decisions to initiate HCV treatment. We analyzed the themes that emerged via the common sense model (CSM) of illness perception theoretical framework.

Results

Using thematic analyses, two major themes emerged related to engagement in HCV treatment. First, participants independently compared HCV to HIV, and in so doing, emphasized the potential fatality of HCV and the need for treatment. Second, participants described witnessing others suffer or die from untreated HCV and expressed how these recollections impacted their desire to undergo treatment themselves. Together, these themes contributed to the way participants perceived HCV and informed their decisions to initiate treatment. Both themes reflect the CSM’s “self-regulation” process, which posits that understanding the causes and consequences of an illness impacts one’s ability to seek treatment to overcome this illness state.

Conclusions

This paper offers insight into how clinicians can better understand and utilize HCV illness perceptions to evaluate willingness to engage in HCV treatment among PWID considering antiviral treatment modalities.

【 授权许可】

   
2015 Safo et al.

【 参考文献 】

• [1]Ward JW. The hidden epidemic of hepatitis C virus infection in the United States: occult transmission and burden of disease. Top Antivir Med. 2013; 21(1):15-9.
• [2]Kohli A, Shaffer A, Sherman A, Kottilil S. Treatment of hepatitis C: a systematic review. JAMA. 2014; 312(6):631-40.
• [3]Naggie S. Management of hepatitis C virus infection: the basics. Top Antivir Med. 2012; 20(5):154-61.
• [4]Sublette VA, Smith SK, George J, McCaffery K, Douglas MW. The hepatitis C treatment experience: patients’ perceptions of the facilitators of and barriers to uptake, adherence and completion. Psychol Health. 2015; 30(8):1-18.
• [5]Yehia BR, Schranz AJ, Umscheid CA, Re VL. The treatment cascade for chronic hepatitis C virus infection in the United States: a systematic review and meta-analysis. PLoS One. 2014; 9(7):e101554.
• [6]Zeremski M, Zibbell JE, Martinez AD, Kritz S, Smith BD, Talal AH. Hepatitis C virus control among persons who inject drugs requires overcoming barriers to care. World J Gastroenterol. 2013; 19(44):7846.
• [7]Grebely J, Dore GJ. Can hepatitis C virus infection be eradicated in people who inject drugs? Antiviral Res. 2014; 104:62-72.
• [8]Bruggmann P, Grebely J. Prevention, treatment and care of hepatitis C virus infection among people who inject drugs. International Journal of Drug Policy. 2014. doi:10.1016/j.drugpo.2014.08.014.
• [9]Zickmund SL, Campbell SA, Tirado CF, Zook CL, Weinrieb RM. Perceived barriers to hepatitis C therapy for patients receiving opioid agonist treatment. J Addict Med. 2012; 6(3):233-9.
• [10]Mravčík V, Strada L, Štolfa J, Bencko V, Groshkova T, Reimer J et al.. Factors associated with uptake, adherence, and efficacy of hepatitis C treatment in people who inject drugs: a literature review. Patient preference and adherence. 2013; 7:1067.
• [11]Swan D, Long J, Carr O, Flanagan J, Irish H, Keating S et al.. Barriers to and facilitators of hepatitis C testing, management, and treatment among current and former injecting drug users: a qualitative exploration. AIDS Patient Care STDS. 2010; 24(12):753-62.
• [12]Barocas JA, Brennan MB, Hull SJ, Stokes S, Fangman JJ, Westergaard RP. Barriers and facilitators of hepatitis C screening among people who inject drugs: a multi-city, mixed-methods study. Harm Reduct J. 2014; 11:1. BioMed Central Full Text
• [13]Treloar C, Rhodes T. The lived experience of hepatitis C and its treatment among injecting drug users: qualitative synthesis. Qual Health Res. 2009; 19(9):1321-34.
• [14]McNeil R, Small W. ‘Safer environment interventions’: a qualitative synthesis of the experiences and perceptions of people who inject drugs. Soc Sci Med. 2014; 106:151-8.
• [15]Arain A, Robaeys G. Eligibility of persons who inject drugs for treatment of hepatitis C virus infection. World J Gastroenterol. 2014; 20(36):12722-33.
• [16]Harris M, Rhodes T. Hepatitis C treatment access and uptake for people who inject drugs: a review mapping the role of social factors. Harm Reduct J. 2013; 10(1):7. BioMed Central Full Text
• [17]Jordan AE, Masson CL, Mateu-Gelabert P, McKnight C, Pepper N, Bouche K et al.. Perceptions of drug users regarding Hepatitis C screening and care: a qualitative study. Harm Reduction Journal. 2013; 10:10. BioMed Central Full Text
• [18]Rosen HR. Chronic hepatitis C infection. N Engl J Med. 2011; 364(25):2429-38.
• [19]Miller ER, McNally S, Wallace J, Schlichthorst M. The ongoing impacts of hepatitis C—a systematic narrative review of the literature. BMC Public Health. 2012; 12:672. BioMed Central Full Text
• [20]Jones L, Atkinson A, Bates G, McCoy E, Porcellato L, Beynon C et al.. Views and experiences of hepatitis C testing and diagnosis among people who inject drugs: systematic review of qualitative research. Int J Drug Pol. 2014; 25(2):204-11.
• [21]Bruggmann P, Litwin AH. Models of care for the management of hepatitis C virus among people who inject drugs: one size does not fit all. Clin Infect Dis. 2013; 57 Suppl 2:S56-61.
• [22]Strauss SM, Munoz-Plaza C, Tiburcio NJ, Astone-Twerell J, Des Jarlais DC, Gwadz M et al.. Barriers and facilitators to undergoing hepatitis C virus (HCV) testing through drug treatment programs. J Drug Iss. 2008; 38(4):1161-85.
• [23]Davis M, Rhodes T, Martin A. Preventing hepatitis C: ‘common sense’, ‘the bug’ and other perspectives from the risk narratives of people who inject drugs. Soc Sci Med. 2004; 59(9):1807-18.
• [24]Rhodes T, Treloar C. The social production of hepatitis C risk among injecting drug users: a qualitative synthesis. Addiction. 2008; 103(10):1593-603.
• [25]Rasi M, Künzler-Heule P, Schmid P, Semela D, Bruggmann P, Fehr J et al.. “ Fighting an uphill battle”: experience with the HCV triple therapy: a qualitative thematic analysis. BMC Infect Dis. 2014; 14:507. BioMed Central Full Text
• [26]Conrad S, Garrett LE, Cooksley WG, Dunne MP, MacDonald GA. Living with chronic hepatitis C means ‘you just haven’t got a normal life any more’. Chronic Illn. 2006; 2(2):121-31.
• [27]Hale ED, Treharne GJ, Kitas GD. The common-sense model of self-regulation of health and illness: how can we use it to understand and respond to our patients’ needs? Rheumatology (Oxford). 2007; 46(6):904-6.
• [28]Leventhal H, Leventhal EA, Breland JY. Cognitive science speaks to the “common-sense” of chronic illness management. Ann Behav Med. 2011; 41(2):152-63.
• [29]Diefenbach MA, Leventhal H. The common-sense model of illness representation: theoretical and practical considerations. Journal of social distress and the homeless. 1996; 5(1):11-38.
• [30]McAndrew LM, Musumeci-Szabó TJ, Mora PA, Vileikyte L, Burns E, Halm EA et al.. Using the common sense model to design interventions for the prevention and management of chronic illness threats: from description to process. Br J Health Psychol. 2008; 13(2):195-204.
• [31]Leventhal H, Meyer D, Nerenz D. The common sense representation of illness danger. Contributions to medical psychology. 1980; 2:7-30.
• [32]Meyer D, Leventhal H, Gutmann M. Common-sense models of illness: the example of hypertension. Health Psychol. 1985; 4(2):115.
• [33]Sutton R, Treloar C. Chronic illness experiences, clinical markers and living with hepatitis C. J Health Psychol. 2007; 12(2):330-40.
• [34]Lang CA, Conrad S, Garrett L, Battistutta D, Cooksley WGE, Dunne MP et al.. Symptom prevalence and clustering of symptoms in people living with chronic hepatitis C infection. J Pain Symptom Manage. 2006; 31(4):335-44.
• [35]Krauskopf K, McGinn T, Federman A, Halm E, Leventhal H, McGinn L et al.. HIV and HCV health beliefs in an innercity community. J Viral Hepat. 2011; 18(11):785-91.
• [36]Munoz-Plaza CE, Strauss S, Astone-Twerell J, Des Jarlais D, Gwadz M, Hagan H et al.. Exploring drug users’ attitudes and decisions regarding hepatitis C (HCV) treatment in the US. Int J Drug Pol. 2008; 19(1):71-8.
• [37]Litwin AH, Berg KM, Li X, Hidalgo J, Arnsten JH. Rationale and design of a randomized controlled trial of directly observed hepatitis C treatment delivered in methadone clinics. BMC Infect Dis. 2011; 11:315. BioMed Central Full Text
• [38]Roose RJ, Cockerham-Colas L, Soloway I, Batchelder A, Litwin AH. Reducing barriers to hepatitis C treatment among drug users: an integrated hepatitis C peer education and support program. J Health Care Poor Underserved. 2014; 25(2):652-62.
• [39]Stein MR, Soloway IJ, Jefferson KS, Roose RJ, Arnsten JH, Litwin AH. Concurrent group treatment for hepatitis C: implementation and outcomes in a methadone maintenance treatment program. J Subst Abuse Treat. 2012; 43(4):424-32.
• [40]Braun V, Clarke V. Using thematic analysis in psychology. Qual Res Psychol. 2006; 3(2):77-101.
• [41]Glaser BG, Strauss AL. The discovery of grounded theory: strategies for qualitative research. Aldine Publishing Company, Chicago, IL; 1967.
• [42]Ly KN, Xing J, Klevens RM, Jiles RB, Ward JW, Holmberg SD. The increasing burden of mortality from viral hepatitis in the United States between 1999 and 2007. Ann Intern Med. 2012; 156(4):271-8.
• [43]Chen E, North C, Fatunde O, Bernstein I, Salari S, Day B et al.. Knowledge and attitudes about hepatitis C virus (HCV) infection and its treatment in HCV mono‐infected and HCV/HIV coinfected adults. J Viral Hepat. 2013; 20(10):708-14.